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Abstract
Summary To determine persistence with subcutaneous
denosumab every 6 months in women being treated for oste-
oporosis, we conducted a single-arm prospective, observa-
tional study in the United States and Canada. Among 935
patients enrolled, 12-month persistence was 82 %, with 66
patients (7 %) reporting serious adverse events and 19 patients
(2 %) reporting fractures.
Introduction Increased persistence with osteoporosis therapy
is associated with reduced fracture risk. Denosumab reduced
fracture risk in clinical trials; persistence in community set-
tings is undetermined. This study evaluates persistence with
denosumab in community practice in the United States (US)
and Canada.
Methods In a 24-month multicenter, prospective, single-arm,
observational study, women being treated for osteoporosis
were enrolled ≤4 weeks after the first subcutaneous injection
of denosumab. For this 12-month prespecified interim analy-
sis, endpoints include persistence (one injection at study entry
and another within 6 months + 8 weeks), attributes associated
with persistence (univariate analysis), and serious adverse
events (SAEs).
Results Among 935 patients (mean age 71 years), mean base-
line T-scores were −2.18 (femoral neck) and −2.00 (lumbar
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spine); 50 % of patients had experienced osteoporotic frac-
ture(s). At 12 months, 82 % of patients were persistent with
denosumab. Baseline factors significantly (p<0.05) associat-
ed with higher persistence included use of osteoporosis med-
ications >5 years previously, lumbar spine T-score > −2.5, and
treatment by female physicians (US). Lower persistence was
associated (p<0.05) with psychiatric diagnoses including de-
pression, southern US residence, being divorced, separated, or
widowed (US), and prior hip fracture (Canada). SAEs were
reported in 66 patients (7 %); no SAEs of osteonecrosis of the
jaw, atypical femoral fracture, fracture healing complications,
hypocalcemia, eczema, or hypersensitivity were reported.
Nineteen patients (2 %) reported osteoporotic fractures.
Conclusions The 12-month persistence observed in this
single-arm open-label study of US and Canadian community
practice extends the evidence regarding denosumab’s poten-
tial role in reducing fracture risk in postmenopausal women
with osteoporosis.
Keywords Adherence . Compliance . Denosumab .
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Introduction
Osteoporotic fractures and the resulting morbidity and
mortality are well documented [1–8], and the public
health impact of these risks will likely increase as the
population ages [9]. Osteoporosis therapies can reduce
fracture risk; agents used include calcium and vitamin D
supplements and prescription therapies. Prescription
agents used in various regions include oral and intrave-
nous bisphosphonates, oral strontium ranelate and ralox-
ifene, subcutaneous denosumab and teriparatide, and
intranasal calcitonin (US) [10, 11]. Nonpersistence with
osteoporosis therapy may increase fracture risk by up to
45 % [12–17], particularly for patients at high risk of
fracture; the associated rates of hospitalization and use
of health care resources also increase [18].
Persistence, a widely used measure of treatment consisten-
cy, i s def ined by the Internat ional Socie ty for
Pharmacoeconomics and Outcomes Research (ISPOR) Med-
ication Compliance and Persistence Work Group as the dura-
tion of time from initiation to discontinuation of therapy [19].
Measures of persistence may include a specific time period
followed by a window of allowable delay, typically ranging
from 30 to 90 days.
Numerous studies have examined persistence with oral
bisphosphonates in patients being treated for osteoporosis,
reporting 12-month persistence rates ranging from 12 to
61 % [15–17, 20]. Fewer studies have assessed persistence
with injected or infused medications. A UK observational
database study of daily self-injected teriparatide (FORTEO®,
Eli Lilly and Company, Indianapolis, Indiana, USA), found
that 87 % of patients were persistent at 12 months [21], with
persistence defined as the duration of treatment. Similarly, in a
US observational study (Direct Analysis of Nonvertebral frac-
tures in the Community Experience; DANCE), 86 % of pa-
tients persisted with teriparatide treatment at 12 months [22].
Zoledronic acid (Reclast® or Aclasta®, Novartis Pharmaceu-
ticals Co., East Hanover, New Jersey, USA) is administered as
an intravenous infusion every 1 or 2 years for the treatment or
prevention of osteoporosis, respectively. In a 2011 clinical
study of elderly patients in South Korea, 12-month persistence
with zoledronic acid was 36 % [23], and a US Medicare
database analysis found that 68 % of zoledronic acid recipi-
ents were persistent at 12 months [24]. In both studies, 12-
month persistence was defined as receiving a second sched-
uled infusion 12 months after the first infusion; no “window”
or grace period before or after 12 months was reported in
either study.
Denosumab (Prolia®, Amgen Inc., Thousand Oaks, Cali-
fornia, USA) is administered as a subcutaneous injection by a
health care professional every 6 months to increase bone mass
in men or treat osteoporosis in postmenopausal women at high
risk of fracture [25, 26]. In the DAPS study (Denosumab
Adherence Preference Satisfaction), 250 patients who had
received at least 6 months of alendronate (FOSAMAX®,
Merck and Co., Inc., Whitehouse Station, New Jersey, USA)
therapy were randomized to denosumab or oral alendronate
for 12months, then switched to the other treatment for another
12 months; study visits were scheduled every 6 months. Per-
sistencewas 90%with denosumab and 80%with alendronate
at 12 months [27] and 97 % with denosumab and 71 % with
alendronate following crossover at the end of the second
12 months [28].
Study of Transi t ioning from Alendronate to
Denosumab (STAND) [29] and Determining Efficacy:
Comparison of Initiating Denosumab versus Alendronate
(DECIDE) [30] were randomized, double-blind, double-
dummy studies that compared the effects of denosumab
and alendronate on bone density and bone turnover
markers. In these studies, persistence at 12 months was
94 and 93 %, respectively, with denosumab and 94 and
91 %, respectively, with alendronate. In the STAND and
DECIDE denosumab clinical studies, patient visits were
scheduled every 3 months.
These studies provide useful information from clinical trial
settings, but evidence is lacking regarding persistence with
denosumab in community practice. It is unknown whether
persistence rates with denosumab are lower outside of clinical
trials. The objectives of this study are to evaluate persistence
with denosumab in postmenopausal women who received
care in routine clinical practice in the US and Canada and to
describe the patients who use denosumab in community
settings.
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Methods
This is a prespecified interim analysis of data for the first
12 months of an ongoing multicenter, single-arm, prospective,
observational, 24-month study being conducted in the US and
Canada. Clinical sites include primary care and specialty
practices caring for postmenopausal women with osteoporo-
sis. Site selection was conducted by a team from the study
sponsor who considered sites based on factors such as physi-
cian interest, availability of patients, presence of clinical staff,
and execution of contracts. Physicians recruited patients dur-
ing regular clinical visits. Participating patients are postmen-
opausal women who received denosumab for the treatment of
osteoporosis according to the applicable US or Canadian
prescribing information. The decision to use denosumab was
made before the patient consented to participate in this study.
Patients were excluded if they had participated in clinical trials
of denosumab at any time or in any other clinical trial during
the previous 6 months, or if they had any disorder that the
investigator believed might compromise their ability to pro-
vide informed consent. Patients were enrolled within 4 weeks
of receiving their first denosumab injection. No study-specific
visits, clinical procedures, laboratory or diagnostic assess-
ments, or changes to routine management of patients were
required. All concomitant medications were allowed if they
were deemed a necessary part of routine clinical care. An
institutional review board (IRB) or ethics committee for each
site approved the protocol and patients provided written in-
formed consent before they were enrolled. Clinical sites at
which women were treated for osteoporosis were selected
from a pharmaceutical industry database to ensure a mix of
practice types and physician specialties; the volume of
denosumab prescriptions was not a consideration in selection
of physicians or study sites.
Data collected
The data cutoff date for this prespecified interim analysis was
December 31, 2012. A questionnaire was completed by each
site to describe characteristics of the physician and site, in-
cluding information about follow-up reminders sent to pa-
tients and reasons for prescribing denosumab.
Standard patient information for routine clinical care was
recorded, including medical history, patient demographics,
bone mineral density, fracture (osteoporotic or other), admin-
istrations of denosumab, previous and concomitant medical
therapies, and comorbidities. Osteoporotic fractures were de-
fined as all fractures excluding skull, facial bones, mandible,
metacarpus, finger phalanges, toe phalanges, and cervical
vertebrae, and not associated with known severe trauma (fall
from higher than the height of stool, chair, first rung on a
ladder or equivalent [>20 in], or severe trauma other than a
fall) or pathological fractures. A comorbidity index adopting
the Wolfe comorbidity index algorithm [31] (modified Wolfe
comorbidity index) was calculated based on the responses
related to the known history of comorbidities. Serious adverse
events (SAEs) reported by physicians were recorded during
the first year of the study; the protocol was subsequently
amended to record all adverse events.
On the day of enrollment, patients were asked to complete
a baseline questionnaire about their health history, including
parental hip fractures, current and past smoking habits, alco-
hol consumption, and recent osteoporosis medication stop-
pages, as well as their income, education level, marital status,
proximity to the treatment site, and use of a denosumab
support program. The questionnaire also collected informa-
tion regarding the type of health care coverage, prior authori-
zation requirements, the denosumab co-payment, and for US
patients enrolled inMedicare Part D (a government-sponsored
prescription medication insurance plan for patients ≥65 years
of age and those with end-stage renal disease), the “donut
hole” (a coverage gap after reaching a spending threshold
during which patients pay a higher price for prescription
medications) [32]. Patients also completed a patient-reported
outcome instrument (SF-12) [33], the Preference and Satis-
faction Questionnaire (PSQ) [34], and the Beliefs about Med-
icine Questionnaire (BMQ-S11) [35]. The SF-12 is a 12-item
survey, with each item assessing broad measures of health
status, and all 12 items adding up to 2 summary scales:
Physical Component Summary and Mental Component Sum-
mary scores. The PSQ assesses patient preference and satis-
faction with medication. The BMQ-S11 assesses positive and
negative beliefs about specific prescribed medication and
provides a numerical assessment of the way in which per-
ceived benefit (necessity) is rated against perceived risk (con-
cerns). Where permitted by regional laws or regulatory guide-
lines, patients could be compensated for inconvenience (e.g.,
completion of questionnaires).
Study endpoints
Study endpoints analyzed at 12months in this 24-month study
include persistence with denosumab at 12 months, defined as
receipt of at least two injections, including one at study entry
and a second no more than 6 months plus 8 weeks (239 days)
later; medicine-taking behavior related to osteoporosis treat-
ment over 12 months; and the occurrence of SAEs in the first
12 months plus 8 weeks. An 8-week window was chosen
because most persistence studies for oral osteoporosis treat-
ments use a 30, 60, or 90-day window [15]. The choice
allowed for a sensitivity analysis within 4- to 12-week win-
dows, as used in other studies. Also, it was thought to reflect
patients in the real-world who would most likely begin think-
ing about returning for the next injection as the 6-month
deadline approached and then would require about 2 months
to make an appointment and secure prior authorization, if
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required. This allowable window is also consistent with the
duration of action demonstrated for denosumab in the treat-
ment of osteoporosis [36]. Additional analyses were conduct-
ed to identify baseline factors that had significant associations
with persistence. Descriptive data were also analyzed to char-
acterize the patients who used denosumab in community
settings.
Statistical analysis
The analysis of persistence was based on total enrollment and
included patients who discontinued denosumab treatment or
withdrew from the study. Summary statistics were provided
for subgroups based on patient demographic and socioeco-
nomic characteristics, medical history, and characteristics of
the physician, clinical site, or health care system. The planned
enrollment was 600 patients from 60 sites in the US and 300
patients from 30 sites in Canada. The planned overall sample
size of 900 patients would allow the half-width of the 95 %
confidence interval (CI) around the point estimate of overall
persistence at the 12- and 24-month time points to be no
greater than 3.3 %. Moreover, the half-width of the 95 % CI
would be no greater than 10% for most potential subgroups of
interest, assuming a subgroup size of 60 patients and a persis-
tence rate of 80 %; the half-width of the 95 % CI would be
13 % for a persistence rate of 50 %. Since enrollment was not
stratified, the actual 95 % CIs would depend on the actual
population characteristics.
Baseline characteristics are summarized using descriptive
statistics (frequency for categorical outcomes and number,
mean, standard deviation [SD], median with interquartile
ranges, or minimum and maximum values for continuous
variables). Persistence rates were reported as percentages
with 95 % CI values calculated using the exact method.
Sensitivity analyses were used to examine different time
windows for the definition of persistence. Data were ana-
lyzed for the overall study population and for individual
countries. Univariate logistic regression analysis was used
to explore association of baseline covariates with persis-
tence in each country. In the univariate analysis, p values
express the statistical significance of each covariate across
all subgroups. SAEs were coded using the Medical Dictio-
nary for Regulatory Activities (MedDRA), tabulated by
system organ class and preferred term, and summarized as
subject incidence.
Results
Enrollment was completed in April 2012. A total of 942
patients agreed to join the study, of whom 935 (632 patients
in the US, 303 in Canada) were enrolled; 7 did not meet
eligibility criteria. At the time of data cutoff for the interim
analysis, 817 patients (87.4 %) remained in the study (544
[86.1 %] in the US, and 273 [90.1 %] in Canada). Of the
patients who discontinued the study, 55 (5.9 %) withdrew
consent, 9 (1.0 %) were lost to follow-up, 8 (0.9 %) died,
and 46 (4.9 %) cited other reasons, with similar distributions
of reasons in both countries.
Patient demographic and physical characteristics
The mean (SD) age of study participants was 70.8 (9.9) years
overall, and nearly three-quarters of patients were aged 65 or
older (Table 1). US patients were slightly older than those in
Canada (71.9 vs. 68.5 years). Most patients (94.8 %) in both
the US and Canada were white or Caucasian. Patients had a
mean (SD) body mass index (BMI) of 25.7 (5.5) kg/m2; more
patients in the US than in Canada had a BMI ≤25 kg/m2 (49.5
vs. 37.6 %). The mean (SD) femoral neck T-score was −2.18
(0.88) and was lower in the US than in Canada: −2.33 (0.77)
vs. −1.87 (1.01), respectively. The overall mean (SD) lumbar
spine T-score was −2.00 (1.31); in contrast with the femoral
neck, T-scores for the lumbar spine were higher in the US than
in Canada: −1.93 (1.34) vs. −2.13 (1.24), respectively
(Table 1).
Osteoporosis-related history
Half of the patients in the study (50.1 %) had a history of
osteoporotic fracture (Table 2). Nonvertebral fractures were
the most common type, reported by 41.6% of patients; 15.9%
of patients had vertebral fractures; and 6.5 % of patients had a
history of hip fracture. Parental hip fractures were reported by
21.0 % of patients.
Nearly all patients (92.0 %) had received a prescription
for osteoporosis medication during the 5 years before en-
rollment, and 58.5 % had received a prescription for oste-
oporosis therapy more than 5 years before enrollment. The
mean (SD) number of previous osteoporosis medications
taken was 2.0 (1.3). Of treatments prescribed for osteopo-
rosis in the last 5 years, the most common were
alendronate, calcium supplements and vitamin D supple-
ments, and risedronate (Table 2). Previous osteoporosis
therapy use was different between countries, possibly be-
cause of differences in regulatory and reimbursement envi-
ronments. Ibandronate had been used only in the US, by
20.3 % of patients; similarly, etidronate had been used only
in Canada, by 9.2 % of patients. Additionally, risedronate
had been used by 41.9 % of patients in Canada but only
26.4 % of US patients, and parathyroid hormone (PTH)/
teriparatide had been used by 23.7 % of US patients but
only 4.3 % of those in Canada.
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Persistence with denosumab
At 12 months, 766 patients (81.9; 95 % CI 79.3–84.3) were
persistent with denosumab; that is, they received a second
denosumab injection within 6 months + 8 weeks after the first
injection (Fig. 1). Persistent patients included 501 (79.3 %) of
those in the US and 265 (87.5 %) in Canada.
In sensitivity analyses, persistence increased as the window
expanded. With a 4-week window, overall persistence was
74.8 % (95 % CI 71.8–77.5); with a 6-week window,
persistence was 80.0 % (95 % CI 77.3–82.5); with a 12-
week window, persistence was 84.8 % (95 % CI 82.3–87.1).
Factors associated with persistence or nonpersistence
From the univariate analyses, several baseline factors showed
a statistically significant association with persistence for pa-
tient subgroups; detailed data are reported in Table 3, and the
list of all factors that were analyzed is presented in Supple-
mentary Table S1. In the US, patient subgroups associated
Table 1 Patient demographic and physical characteristics
Characteristic Overall US Canada
N=935 N=632 N=303
Age, years
Mean (SD) 70.8 (9.9) 71.9 (10.0) 68.5 (9.2)
<65, n (%) 267 (28.6) 152 (24.1) 115 (38.0)
65 to <75, n (%) 318 (34.0) 216 (34.2) 102 (33.7)
≥75, n (%) 350 (37.4) 264 (41.8) 86 (28.4)
Race or ethnicity, n (%)
White or Caucasian 886 (94.8) 601 (95.1) 285 (94.1)
Asian 25 (2.7) 9 (1.4) 16 (5.3)
Black or African American 9 (1.0) 9 (1.4) 0 (0.0)
Othera 15 (1.6) 13 (2.1) 2 (0.7)
Marital status, n (%)
Married 512 (54.8) 320 (50.6) 192 (63.4)
Never married 46 (4.9) 26 (4.1) 20 (6.6)
Divorced/separated/widowed 373 (39.9) 282 (44.6) 91 (30.0)
Missing 4 (0.4) 4 (0.6) 0 (0.0)
Body mass index
Mean (SD) 25.7 (5.5) 25.4 (5.7) 26.2 (5.0)
≤25 kg/m2, n (%) 427 (45.7) 313 (49.5) 114 (37.6)
>25 kg/m2, n (%) 379 (40.5) 237 (37.5) 142 (46.9)
Missing, n (%) 129 (13.8) 82 (13.0) 47 (15.5)
Modified Wolfe comorbidity index, median (Q1, Q3) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0) 2.0 (1.0, 3.0)
Number of prescription medications taken at baseline, median (Q1, Q3) 7.0 (4.0, 10.0) 8.0 (5.0, 11.0) 5.0 (3.0, 7.0)
Baseline bone mineral density
Femoral neck T-score
Mean (SD) −2.18 (0.88) −2.33 (0.77) −1.87 (1.01)
≤−2.5, n (%) 351 (37.5) 272 (43.0) 79 (26.1)
>−2.5, n (%) 508 (54.3) 313 (49.5) 195 (64.4)
Missing, n (%) 76 (8.1) 47 (7.4) 29 (9.6)
Lumbar spine T-score
Mean (SD) −2.00 (1.31) −1.93 (1.34) −2.13 (1.24)
≤−2.5, n (%) 357 (38.2) 228 (36.1) 129 (42.6)
>−2.5, n (%) 492 (52.6) 341 (54.0) 151 (49.8)
Missing, n (%) 86 (9.2) 63 (10.0) 23 (7.6)
SD standard deviation, Q1, Q3, 25th and 75th percentile, US United States
a Other race includes mixed race, American Indian or Alaska Native, Native Hawaiian or other Pacific Islander, or other (not specified)
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with higher persistence included those who used osteoporosis
medications during the period more than 5 years before en-
rollment (83.3 vs. 73.9 %), patients with lumbar spine T-
scores > –2.5 (82.7 vs. 75.9 % for T-scores ≤ −2.5), and those
treated by female physicians (85.1 vs. 77.3 %; Table 3).
Patients whose BMQ-S11 necessity-concerns differential
score (the ratio of beliefs about the necessity of treatment to
concerns about potential negative aspects of treatment) was
higher than the median score of 0.57 had a higher persistence
rate (83.9 %) than those with scores below the median
(76.5 %). Among the subgroups with lower persistence were
US patients who reported depression or other psychiatric
diagnoses at baseline compared with patients without these
comorbidities (72.5 vs. 82.2 %); patients who were divorced,
widowed, or separated (74.5 %) compared with those who
were married (83.8 %) or never married (76.9 %); and US
residents from the South (72.2 %) compared with those from
the Midwest (87.0 %), Northeast (83.3 %), and West (80.0 %).
Among Canadian patients, patients with a history of hip
fracture had lower persistence (60.0 %) compared with those
with no history of hip fracture (88.9 %). Those who selected
the response not applicable (NA) to a question about the need
for prior authorization had a lower rate of persistence (65.0 %)
than those who responded yes (87.9 %) or no (91.3 %).
Table 2 Osteoporosis-related patient history and medication use
Characteristic Overall US Canada
N=935 N=632 N=303
Any history of fracture, n (%) 525 (56.1) 361 (57.1) 164 (54.1)
Osteoporotic fracture, n (%)a 468 (50.1) 324 (51.3) 144 (47.5)
Vertebral 149 (15.9) 104 (16.5) 45 (14.9)
Nonvertebral 389 (41.6) 270 (42.7) 119 (39.3)
Major nonvertebralb 261 (27.9) 178 (28.2) 83 (27.4)
Hip 61 (6.5) 46 (7.3) 15 (5.0)
More than one fracture, n (%) 246 (26.3) 173 (27.4) 73 (24.1)
Time since the most recent fractures, n (%)
<12 months 67 (7.2) 39 (6.2) 28 (9.2)
≥12 months 456 (48.8) 320 (50.6) 136 (44.9)
Parent had hip fracture, n (%) 196 (21.0) 127 (20.1) 69 (22.8)
Osteoporosis medication
Any exposure to prior prescription osteoporosis therapy prior to enrollment, n (%) 867 (92.7) 587 (92.9) 280 (92.4)
Exposure to prior prescription osteoporosis therapy during the period >5 years prior to enrollment, n (%) 547 (58.5) 360 (57.0) 187 (61.7)
Number of prior osteoporosis medications taken, mean (SD) 2.0 (1.3) 2.0 (1.3) 2.0 (1.2)
Osteoporosis medications prescribed in the last 5 years, n (%)
Alendronate 398 (42.6) 255 (40.3) 143 (47.2)
Calcium supplements and vitamin D supplements 376 (40.2) 232 (36.7) 144 (47.5)
Risedronate 294 (31.4) 167 (26.4) 127 (41.9)
Zoledronic acid 168 (18.0) 123 (19.5) 45 (14.9)
PTH/Teriparatide 163 (17.4) 150 (23.7) 13 (4.3)
Ibandronate 128 (13.7) 128 (20.3) 0 (0.0)
Hormone replacement therapy 45 (4.8) 24 (3.8) 21 (6.9)
Raloxifene 42 (4.5) 27 (4.3) 15 (5.0)
Other (non-bisphosphonate) 31 (3.3) 26 (4.1) 5 (1.7)
Etidronate 28 (3.0) 0 (0.0) 28 (9.2)
Calcitonin 28 (3.0) 16 (2.5) 12 (4.0)
Other bisphosphonate 6 (0.6) 3 (0.5) 3 (1.0)
Strontium ranelate 2 (0.2) 0 (0.0) 2 (0.7)
PTH parathyroid hormone, SERM selective estrogen receptor modulator, SD standard deviation, US United States
a Any fracture recorded on the case report form, excluding skull, facial bones, mandible, metacarpus, finger phalanges, toe phalanges, and cervical
vertebrae and not associated with known severe trauma (fall from higher than the height of stool, chair, first rung on a ladder or equivalent [>20 in], or
severe trauma other than a fall) or pathological fractures
b A subset of nonvertebral fractures including the following locations: pelvis, hip, lower leg (not knee or ankle), ribs, shoulder, forearm, and wrist and not
associated with known severe trauma or pathological fractures
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Comorbidities and risk factors
Osteoarthritis was the most common comorbidity, reported by
52.7 % of the patients in this study (Supplementary Table S2).
Hypertension and back pain were also reported by more than
half of patients overall, and gastrointestinal disorders were
reported by 44.9 % of patients overall. The median (Q1, Q3)
modifiedWolfe comorbidity index in both the US and Canada
was 2.0 (1.0, 3.0; Table 1). Patients in the US were taking a
median (Q1, Q3) of 8.0 (5.0, 11.0) prescription medications at
baseline, compared with 5.0 (3.0, 7.0) for patients in Canada.
Three key risk factors for osteoporotic fracture are age
≥65 years, T-score ≤ −2.5, and a history of osteoporotic
fracture. In this study, nearly all patients (93.9 %) had at least
one of these risk factors, 414 patients (44.3 %) had two of
these risk factors, and 209 patients (22.4 %) had all three risk
factors (Table 4). In this population, age was the largest
contributor to overall risk; 668 of the 935 patients (71.4 %)
in the study were aged ≥65 years. The next most common risk
factors were T-score ≤ −2.5 at either the femoral neck or
lumbar spine (574 patients, 61.4 %) and a history of osteopo-
rotic fracture (468 patients, 50.1 %).
Physician and site characteristics
A total of 135 clinical sites were contacted, of which 80 sites
enrolled at least 1 subject (US, 54; Canada, 26). Physician and
site characteristics are described in Supplementary Table S3.
The most common physician specialties were rheumatology
(n=22, 41 %) and internal medicine (n=12, 22 %) in the US,
and family practice (n=8, 31 %) and endocrinology (n=6,
23 %) in Canada. Most physicians in both countries were men
(US: n=39, 72 %; Canada: n=19, 73 %), were in private
practices (US: n=49, 91 %; Canada: n=20, 77 %), and had
at least 10 years of experience in practice (US: n=47, 87 %;
Canada: n=26, 100 %). Two-thirds of physicians in the US
(n=36, 67 %) and half in Canada (n=13, 50 %) were in group
practices; the others were sole practitioners.
Reasons for prescribing denosumab
Among all patients in the study, the most common reason for
prescribing denosumab was that the patient had multiple risk
factors for fracture (as defined by the physician), cited by 54.1%
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b
Fig. 1 Persistence with
denosumab at 12 months. a
Primary analysis: percentage of
patients who received a second
injection of denosumab within
6 months + 8 weeks. b Sensitivity
analyses: percentage of patients
who received a second injection
of denosumab within 6 months +
4, 6, or 12 weeks. The dashed
lines in b represent the proportion
of patients who were persistent at
the primary endpoint time
window of 6 months + 8 weeks.N
number of patients in the overall
cohort and in each country. n
number of patients who were
persistent in each group. CI
confidence interval, US United
States
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failure of other available osteoporosis therapies (42.4%), patient
intolerance of other osteoporosis therapies (32.0 %), and a
history of osteoporotic fracture (29.3 %). More than one reason
could be cited for prescribing denosumab for each patient.
Table 3 Baseline factors that show statistically significant association with persistence by country
Country Covariate Category Persistence (%) Odds ratio (95 % CI) p value

















































































Univariate analysis. The p value represents the statistical significance of the covariate when added to the univariate logistic model, with persistence as the
response variable
BMQ-S11 Beliefs About Medicine Questionnaire, CI confidence interval, NA not applicable, US United States
a Statistically significant because of large number of patients in NA category
Table 4 Risk factors for osteoporosis
Risk factors, n (%) Overall US Canada
N=935 N=632 N=303
Age ≥65 years 668 (71.4) 480 (75.9) 188 (62.0)
T-score ≤−2.5a 574 (61.4) 394 (62.3) 180 (59.4)
≥1 historical osteoporotic fractureb 468 (50.1) 324 (51.3) 144 (47.5)
Number of risk factors
0 57 (6.1) 26 (4.1) 31 (10.2)
1 of the following risk factors: 255 (27.3) 159 (25.2) 96 (31.7)
Age ≥65 years old 118 (12.6) 84 (13.3) 34 (11.2)
T-score ≤ −2.5a 99 (10.6) 53 (8.4) 46 (15.2)
≥1 historical osteoporotic fractureb 38 (4.1) 22 (3.5) 16 (5.3)
2 of the following risk factors: 414 (44.3) 302 (47.8) 112 (37.0)
Age ≥65 years old and T-score ≤−2.5a 193 (20.6) 145 (22.9) 48 (15.8)
Age ≥65 years old and ≥1 historical osteoporotic fractureb 148 (15.8) 106 (16.8) 42 (13.9)
T-score ≤−2.5a and ≥1 historical osteoporotic fractureb 73 (7.8) 51 (8.1) 22 (7.3)
3 risk factors (age ≥65 years old, T-score ≤−2.5,
and ≥1 historical osteoporotic fracture)
209 (22.4) 145 (22.9) 64 (21.1)
US United States
a T-score at femoral neck or lumbar spine
bAny fracture recorded on the case report form, excluding skull, facial bones, mandible, metacarpus, finger phalanges, toe phalanges, and cervical
vertebrae and not associated with known severe trauma (fall from higher than the height of stool, chair, first rung on a ladder or equivalent [>20 in] or
severe trauma other than a fall) or pathological fractures
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Among patients with none of the three key risk factors for
osteoporotic fracture (age ≥65 years, T-score ≤ −2.5, and a
history of osteoporotic fracture), physicians cited multiple risk
factors for fracture (as defined by the physician) as a reason for
prescribing denosumab for 61.4 % of patients; failure of other
osteoporosis therapies (35.1 %) and intolerance of other osteo-
porosis therapies (28.1 %) were also cited.
Safety
SAEs were reported for 66 patients (7.1 %), including 51
(8.1 %) in the US and 15 (5 %) in Canada (Table 5). Five
patients reported SAEs (0.5 %) that led to discontinuation of
denosumab. Three patients (0.3 %) had SAEs that led to
withdrawal from the study. Nine patients (1.0 %) had fatal
SAEs, none of which were considered related to denosumab
by the investigator. Of these, fatal SAEs of infection occurred
in five patients: two cases of Clostridium difficile colitis (one
with a history of ulcerative colitis and past history ofC. difficile
infection; one with chronic diarrhea, chronic pancreatitis, and
chronic renal failure and possible pneumonia); one case of
device-related sepsis (the patient was hospitalized for digoxin
toxicity requiring hemodialysis for acute renal failure); one
event of pneumonia (in the context of underlying chronic
obstructive pulmonary disease [COPD]); and a local hand
infection with subsequent progression to necrotizing fasciitis
with protracted course in a patient with multiple comorbidities
including diabetes mellitus and past medical history that in-
cluded shingles, arm abscess, and gluteal furuncle. Four addi-
tional fatalities included two patients with histories of ovarian
cancer who died of metastatic cancer, and one patient with
underlying coronary artery disease, congestive heart failure,
and COPD who died from cardiac arrest. The death of a 92-
year-old patient was reported to be from natural causes.
Fracture data were collected as adverse events and review
of radiographs was not adjudicated. Nineteen patients experi-
enced a total of 27 osteoporotic fractures (Table 5). Of the
patients who experienced osteoporotic fractures during the
study, 13 (68.4 %) had a history of prior osteoporotic fracture.
There were no reports of atypical femoral fracture or
osteonecrosis of the jaw, or SAEs of fracture healing compli-
cations, hypocalcemia, eczema, or hypersensitivity.
Discussion
This analysis reports 12-month interim data from a prospec-
tive, observational, single-arm, open-label study of postmen-
opausal women in the US and Canada who received
denosumab for treatment of osteoporosis as part of routine
clinical care in accordancewith the local approved label. More
than 80 % of these patients were persistent with their second
injection of denosumab therapy. Univariate analyses of factors
associated positively with higher or lower persistence in the
first year varied widely and were different between the US and
Canada. Safety results in this study were consistent with those
observed in previous studies of denosumab, and no new safety
signals were identified. The types of SAEs identified reflect
complex medical histories of study participants at high risk for
fracture who were enrolled in this observational evaluation.
The importance of persistence in reducing fracture risk has
been established [12–17]. Multiple studies have provided data
regarding 12-month persistence for other oral, infused, and
injected osteoporosis therapies [15, 17, 20–24]. Additionally,
12-month persistence with denosumab was reported from
three randomized controlled clinical trials [27, 28, 30]. The
current observational study contributes needed evidence re-
garding the willingness of patients to persist with denosumab
treatment outside the setting of a clinical trial, in routine
community practice. In our study, persistence with denosumab
at 12 months was 82 %, a relatively small difference from the
90, 94, and 93 % rates observed at 12 months in the DAPS,
STAND, and DECIDE clinical studies of denosumab [27, 29,
30]. In contrast, rates of 12-month persistence with oral
bisphosphonates in community settings have been reported
to range from 12 to 61 % [14, 17].
In comparison, studies of injected teriparatide found 12-
month persistence rates of 86 and 87 % [21, 22]. Several
factors contribute to these high rates of persistence. In the
2006 report of the UK teriparatide study, the authors noted that
patients cannot receive teriparatide in the UK health care
system unless they have sustained several fractures, have
failed or have been intolerant to a bisphosphonate, received
the prescription from a specialist, and participated in an
Table 5 Serious adverse events and fractures
Event, patient incidence, n (%) Overall US Canada
N=935 N=632 N=303
All SAEs 66 (7.1) 51 (8.1) 15 (5.0)
SAEs leading to discontinuation
of denosumab
5 (0.5) 3 (0.5) 2 (0.7)
SAEs leading to withdrawal from
the study
3 (0.3) 3 (0.5) 0 (0.0)
Fatal adverse eventsa 9 (1.0) 7 (1.1) 2 (0.7)
Osteoporotic fracturesb, c 19 (2.0) 18 (2.8) 1 (0.7)
SAE serious adverse event, US United States
a One death, which occurred after the data cut-off for this analysis,
resulted from an SAE that began during the interim data analysis period
bAny fracture recorded on the case report form, excluding skull, facial
bones, mandible, metacarpus, finger phalanges, toe phalanges, and cer-
vical vertebrae and not associated with known severe trauma (fall from
higher than the height of stool, chair, first rung on a ladder or equivalent
[>20 in] or severe trauma other than a fall) or pathological fractures
c On-study osteoporotic fractures were as follows: 1 carpus, 2 fibula, 2
humerus, 5 spine, 5 metatarsus, 2 patella, 1 pubis, 2 radius, 1 rib, 5 tarsus,
1 tibia
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education and nurse-led follow-up program; these restrictions
might contribute to a selected population that may be more
inclined to be persistent than other patients [21]. In the 2011
study of US patients, Gold et al. [22] noted that 59 % of
patients believed their osteoporosis was severe or very severe,
96 % believed it was very or extremely important to treat their
osteoporosis, and 84 % believed that teriparatide would be
very or extremely effective in reducing fracture risk; these
factors were thought to have contributed to high levels of
persistence. Some patients participated in an optional patient
support program, which might also have affected persistence.
Additionally, the authors noted that many of the study inves-
tigators in the DANCE study were considered national experts
who might not be representative of other prescribers. These
factors complicate comparison between the denosumab and
teriparatide persistence rates.
Two studies of infused zoledronic acid for osteoporosis found
persistence rates of 36 and 68 % at 12 months [23, 24]. Neither
of these zoledronic acid studies specifically analyzed variations
in community practices or the effects of 2-year dosing for
prevention, an approved indication in some regions, so these
data may not reflect current community practice.
Since few studies have evaluated persistence in infrequent-
ly injected treatments such as denosumab, there is little pre-
cedent for the methods used to define persistence. In the
studies of daily teriparatide, definitions of persistence were
simple—the duration of treatment [21] and not reporting
discontinuation [22]. In the DAPS study, persistence with
denosumab was defined as receiving two injections and com-
pleting the treatment period [27]. In our study, the endpoint of
persistence allowed for a window of 8 weeks following the 6-
month treatment interval. This allowable window is consistent
with the duration of action demonstrated for denosumab in the
treatment of osteoporosis [36]. The 8-week window also
recognizes that many patients would most likely begin think-
ing about returning for the next injection as the 6-month
deadline approached and then would need about 2 months to
make an appointment and secure prior authorization, if re-
quired. However, sensitivity analyses of results for windows
of 6 months + 4, 6, or 12 weeks showed only minor differ-
ences in persistence results.
Three key risk factors for osteoporotic fracture are age
≥65 years, T-score ≤ −2.5, and a history of osteoporotic
fracture [11, 37]. Whether these risk factors are associated
with persistence has been inconsistent. The effects of both age
and previous fracture have varied among studies [38]. In this
study, age did not appear to be associated with persistence
based on statistical significance from a univariate analysis;
similarly, previous hip fracture and lower T-scores were not
associated with higher persistence. As might be expected,
depression and/or other psychiatric diagnoses were associated
with a lower rate of persistence for US patients, but this
relationship was not significant in Canada. In some subgroups
of patients, such as those who used bisphosphonates during
the period more than 5 years before enrollment, patients
treated by female physicians, those residing in specific re-
gions, and married patients, persistence was surprisingly high
compared with other subgroups—but even these were incon-
sistent between the US and Canada. Except for the physician’s
gender, factors related to the physician or medical practice
(e.g., specialty or use of reminders) were not statistically
significantly associated with persistence, perhaps due to the
high rate of overall persistence.
Schousboe argues that patients’ beliefs, concerns, and sat-
isfaction with treatments are major contributors to persistence;
he contends that more study is needed to understand these
factors [38]. Some studies have recently addressed that need.
Barrett-Connor et al. [39] confirmed the role of patient satis-
faction in persistence with osteoporosis treatment. Kendler
et al. [40] explored the influence on persistence of patients’
beliefs about their personal need for osteoporosis treatment
and their potential concerns about possible adverse conse-
quences for taking it. The authors found a higher degree of
belief in the necessity of osteoporosis medication and a lower
degree of concern about adverse consequences (the necessity-
concerns differential score) were associated with better adher-
ence in some time periods measured. In that study, preference
for denosumab vs. alendronate was associated with higher
persistence. In the current analysis, a greater necessity-
concerns differential score had a higher odds ratio for persis-
tence for US patients. Patients in our observational study had
already declared their preference for denosumab when they
decided to receive treatment prior to study enrollment. More
research is needed to identify factors that will influence pa-
tients to persist with osteoporosis therapy. In view of the
compelling research linking persistence and compliance to
reduction of fractures, this research is critical. In addition,
primary nonadherence (the initial refusal of the recommenda-
tion to begin fracture prevention medication) is another im-
portant topic that warrants further study. In particular, the
characteristics of those who fall into this category need to be
explicated.
This study has some limitations. The analysis of factors
associated with persistence is not easy to interpret or to apply
in clinical practice or policy decision-making. This 12-month
analysis was not designed to evaluate the interactions between
12-month persistence and the risk of fracture due to the
observational nature and short time frame of this analysis.
Because neither physicians nor patients were asked the rea-
sons for delay or discontinuation, potential reasons (e.g.,
patient illness and switch to another treatment) are unknown.
It is possible that physicians who participated in this study
were not representative of the overall population of physicians
who treat women with osteoporosis. For example, physicians
in this study were interested in participating in research, and
their practices had the infrastructure to do so, which may not
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be the case for all physicians and sites. These physicians
began enrolling patients beginning a year following the avail-
ability of denosumab and may have been early users of the
product. This fact may suggest actions that may be used in
some offices to encourage patient return that were not cap-
tured in the physician site survey. Similarly, the patients in this
study might not have been representative of the overall pop-
ulation in that they were willing to participate in a research
study. Also, the patients in these studies knew in advance that
their medication use behavior was being observed, unlike
retrospective studies of pharmaceutical claims databases.
They were candidates for, and approximately half participated
in, a voluntary denosumab patient support program, potential-
ly benefiting their persistence in the study; the influence of
such programs is unknown. The reimbursement landscape
differences between the US and Canada may explain some
of the differences in persistence between the countries. How-
ever, because reimbursement systems varied between the US
and Canada and among regions in each country, the effects of
reimbursement and cost-sharing systems could not be precise-
ly assessed. Regarding safety, decreased surveillance in rou-
tine clinical practice compared with randomized, controlled
clinical trials may have impacted the SAEs reported.
These limitations do not outweigh the strengths of this
study, which include the prospective observational design
and the wide range of practice types, North American regions,
and patients represented in the study. While the results may
not be generalizable to all patients, they are more likely than
clinical trial analyses of persistence to provide insights into
real-world use of twice-yearly denosumab therapy.
Overall, this study provides important new evidence
concerning persistence with denosumab therapy in communi-
ty practice settings. Whereas persistence with oral osteoporo-
sis treatments has been analyzed, limited data are available for
an injected twice-yearly medication. Future studies should
consider the relationship between persistence with
denosumab and the incidence of fracture, perhaps in
comparison with other osteoporosis therapies. The study
lays the groundwork for such additional research to clarify the
factors that would increase persistence among denosumab
users and thereby reduce the risk of fractures in women with
osteoporosis.
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